Asunto(s)
Genética Médica , Humanos , Genómica , Pruebas Genéticas , Células Germinativas , Quinasa de Punto de Control 2Asunto(s)
Infecciones por Coronavirus , Gripe Humana , Pandemias , Neumonía Viral , Betacoronavirus , COVID-19 , Hospitales , Humanos , Gripe Humana/epidemiología , SARS-CoV-2Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Colesterol/sangre , Técnicas de Apoyo para la Decisión , Dislipidemias/epidemiología , Anticolesterolemiantes/uso terapéutico , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & control , Toma de Decisiones Clínicas , Comorbilidad , Dislipidemias/sangre , Dislipidemias/diagnóstico , Dislipidemias/terapia , Humanos , Selección de Paciente , Valor Predictivo de las Pruebas , Pronóstico , Medición de Riesgo , Factores de Riesgo , Factores de TiempoRESUMEN
The human DNA repair enzyme MUTYH excises mispaired adenine residues in oxidized DNA. Homozygous MUTYH mutations underlie the autosomal, recessive cancer syndrome MUTYH-associated polyposis. We report a MUTYH variant, p.C306W (c.918C>G), with a tryptophan residue in place of native cysteine, that ligates the [4Fe4S] cluster in a patient with colonic polyposis and family history of early age colon cancer. In bacterial MutY, the [4Fe4S] cluster is redox active, allowing rapid localization to target lesions by long-range, DNA-mediated signalling. In the current study, using DNA electrochemistry, we determine that wild-type MUTYH is similarly redox-active, but MUTYH C306W undergoes rapid oxidative degradation of its cluster to [3Fe4S]+, with loss of redox signalling. In MUTYH C306W, oxidative cluster degradation leads to decreased DNA binding and enzyme function. This study confirms redox activity in eukaryotic DNA repair proteins and establishes MUTYH C306W as a pathogenic variant, highlighting the essential role of redox signalling by the [4Fe4S] cluster.
Asunto(s)
Poliposis Adenomatosa del Colon/metabolismo , Neoplasias del Colon/metabolismo , ADN Glicosilasas/metabolismo , Proteínas Hierro-Azufre/metabolismo , ADN Glicosilasas/genética , Variación Genética/genética , Humanos , Mutación , Oxidación-ReducciónRESUMEN
The Canadian Hypertension Education Program (CHEP) has published guidelines annually since 2000. The CHEP guidelines are a model of concise, comprehensive, up-to-date, evidence-rated guidelines for physicians who diagnose and treat hypertension. The guidelines address measurement of blood pressure and the definition of hypertension, secondary hypertension evaluation and treatment, and blood pressure targets and medication choices in patients with and without compelling indications. This review describes CHEP's process for developing guidelines and provides an overview of the 2013 recommendations.
Asunto(s)
Manejo de la Enfermedad , Hipertensión/terapia , Guías de Práctica Clínica como Asunto , Presión Sanguínea/fisiología , Canadá/epidemiología , Medicina Basada en la Evidencia , Humanos , Hipertensión/epidemiología , Hipertensión/fisiopatologíaRESUMEN
Patients don't have an "individual risk" or unique probability of an outcome. Outside Mendelian inheritance, risks are conditional probabilities and differ as the risk factors included differ, at times substantially. This lack of reliability is an inherent limitation and is not resolved by including additional risk factors. Groups of like individuals need to be assembled to measure the probability of an outcome. Many groups, like any individual, can be identified, eg, groups of the same age, sex, race, or any combination of these attributes (or any others). That each of these groups may have different risk means there is no such thing as individual risk. This issue was identified by John Venn in 1866 and is known as the reference class problem. Models relate risk factors to outcomes in populations. The number calculated for an individual should not be reported as their individual or true risk, nor should it be used as the sole criterion for clinical decisions. Instead, Feinstein proposed relying on clinically important subgroups. An example would be utilizing an individual's blood pressure as the primary determinant of hypertension treatment decisions, not an unreliable individual risk estimate.
Asunto(s)
Valor Predictivo de las Pruebas , Probabilidad , Medición de Riesgo/métodos , Biomarcadores , Humanos , Modelos Teóricos , PronósticoAsunto(s)
Antihipertensivos/efectos adversos , Cefalea/inducido químicamente , Pirosis/inducido químicamente , Hipertensión/tratamiento farmacológico , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/fisiopatología , Factores de RiesgoRESUMEN
Flushing and hepatotoxicity are important adverse effects of nicotinic acid. This article reviews the role of metabolism of nicotinic acid in the production of these side effects. The suggestion that nicotinic acid (NUA) formation produces flushing is traced to a correlation of flushing with NUA C(max) (maximal concentration) and the observation that aspirin inhibits NUA formation and flushing. The former does not establish causation and the latter can be explained by inhibition of prostaglandin formation. Recent characterization of the GPR109A receptor that mediates prostaglandin release by Langerhans cells to produce flushing has shown nicotinic acid, not NUA, is responsible. The suggestion that nicotinamide metabolites produce hepatotoxicity is not supported by any data. The mechanism of hepatotoxicity is unknown and a toxic metabolite of nicotinic acid has not been identified. Different nicotinic acid formulations produce different metabolite patterns due to nonlinear pharmacokinetics, but there is no evidence that these differences have any clinical importance.
RESUMEN
Avasimibe, an acyl-CoA:cholesterol acyltransferase inhibitor, has been previously shown to be a potent inducer of CYP3A4 and multiple drug resistance protein 1. We have further characterized the drug interaction potential of avasimibe by studying the inductive and inhibitory effect of this compound on major drug-metabolizing enzymes. Enzymes known to be involved in the metabolism of drugs likely to be coadministered with avasimibe, such as CYP1A1/2, CYP2C, and CYP2B6, were evaluated further by microarray analysis, Western immunoblotting, and activity assays, using rifampicin and beta-naphthoflavone as positive controls. No change was observed in CYP1A1/2 mRNA or activity levels after avasimibe treatment. Differential induction of CYP2C9- and CYP2B6-immunoreactive protein and activity was observed depending on drug concentration and donor. Microarray analysis showed a similar increase in CYP2C and CYP2B6 mRNA levels. The inhibition potential of avasimibe on the major drug-metabolizing enzymes was assessed using pooled human liver microsomes. Avasimibe inhibited CYP2C9 (IC50 2.9 microM), CYP1A2 (IC50 13.9 microM), and CYP2C19 (IC50 26.5 microM). A clinical drug interaction study was conducted to determine whether avasimibe might interact with the CYP2C9 substrate warfarin. Volunteers received 750 mg of avasimibe and showed a 54.2% reduction in trough concentrations of S-warfarin and decreased prothrombin times by 12, 15, 19, and 21% on days 6 through 9, respectively. These results demonstrate that avasimibe's inductive spectrum resembles that of rifampin.
Asunto(s)
Acetatos/farmacología , Hidrocarburo de Aril Hidroxilasas/biosíntesis , Inhibidores Enzimáticos/farmacología , Ácidos Sulfónicos/farmacología , Acetamidas , Anticoagulantes/farmacocinética , Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Hidrocarburo de Aril Hidroxilasas/metabolismo , Western Blotting , Células Cultivadas , Citocromo P-450 CYP1A1/antagonistas & inhibidores , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1A2/metabolismo , Inhibidores del Citocromo P-450 CYP1A2 , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP2C9 , Inducción Enzimática/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Cinética , Análisis de Secuencia por Matrices de Oligonucleótidos , Oxidorreductasas N-Desmetilantes/antagonistas & inhibidores , Oxidorreductasas N-Desmetilantes/metabolismo , Preparaciones Farmacéuticas/metabolismo , Receptor X de Pregnano , Tiempo de Protrombina , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptores Citoplasmáticos y Nucleares/antagonistas & inhibidores , Receptores de Esteroides/antagonistas & inhibidores , Esterol O-Aciltransferasa/antagonistas & inhibidores , Sulfonamidas , Warfarina/farmacocinéticaRESUMEN
In vitro and clinical studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions. Clinically, 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were observed after 50 and 750 mg of avasimibe daily for 7 days, respectively. A 40% decrease in digoxin (P-glycoprotein substrate) area under the curve was observed with 750 mg of avasimibe daily for 10 days. In vitro studies were conducted to define the mechanisms of these interactions. Induction was observed in CYP3A4 activity and immunoreactive protein (EC50 of 200-400 nM) in primary human hepatocytes treated with avasimibe. Rifampin treatment yielded similar results. Microarray analysis revealed avasimibe (1 microM) increased CYP3A4 mRNA 20-fold, compared with a 23-fold increase with 50 microM rifampin. Avasimibe induced P-glycoprotein mRNA by about 2-fold and immunoreactive protein in a dose-dependent manner. Transient transfection assays showed that avasimibe is a potent activator of the human pregnane X receptor (hPXR) and more active than rifampin on an equimolar basis. Drug-drug interaction studies for CYP3A4 using pooled human hepatic microsomes and avasimibe at various concentrations, revealed IC50 values of 20.7, 1.6, and 3.1 microM using testosterone, midazolam, and felodipine as probe substrates, respectively. Our results indicate that avasimibe causes clinically significant drug-drug interactions through direct activation of hPXR and the subsequent induction of its target genes CYP3A4 and multiple drug resistance protein 1.